Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:
23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
ChinaTianyin Pharmaceutical Co., Inc.Consolidated Balance Sheets(Unaudited)September 30,June 30,20132013AssetsCurrent assets:Cash and cash equivalents$
26,827,008Restricted cash4,564,0004,536,000Accounts receivable, net of allowance for doubtful accounts o
|SOURCE Tianyin Pharmaceutical Inc.|
Copyright©2012 PR Newswire.
All rights reserved